Negen opens a free COVID-19 pharmacogenomics panel
Negen opens a new pharmacogenomics panel. Panel focuses on pharmacogenomic effects of the medicines suggested for severe COVID-19 infection treatment. This panel is available free of charge for everyone having existing genome data from other sources, for example 23andMe and other ancestry services.
This year, HIMSS Europe, the premier event in digital health, will be held in Finland (11.-13.6). Messukeskus Helsinki expects thousands of participants from around the world representing ministries, hospitals, and health technology companies.
Negen genomic analyses now available via Terveystalo
Finland’s largest health service provider Terveystalo maintains its role as pioneer by being the first to include Negen’s genomic tests in its offering.
Genomic testing provides the earliest indication of elevated disease risk
Early identification of disease risk enables effective prevention, which translates to more years of healthy living for the individual and significantly reduced healthcare costs.
Negen partners with BC Platforms for early risk assessment of common diseases
Negen is excited to announce a cooperation agreement with BC Platforms, a leading provider of genomic data management and analytics. Negen’s advanced Genetic Risk Scoring tools will be integrated with BC Platforms’ state-of-the-art genomic data management platform, leading to advances in data processing and interpretation. Working together, these two leading genomics data companies will provide a premium, integrated solution to healthcare providers and customers around the world.
